AR089122A1 - Formulaciones orales para tratar la sobrecarga de metales - Google Patents
Formulaciones orales para tratar la sobrecarga de metalesInfo
- Publication number
- AR089122A1 AR089122A1 ARP120104611A ARP120104611A AR089122A1 AR 089122 A1 AR089122 A1 AR 089122A1 AR P120104611 A ARP120104611 A AR P120104611A AR P120104611 A ARP120104611 A AR P120104611A AR 089122 A1 AR089122 A1 AR 089122A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- integer
- hydrogen
- independently selected
- alkoxy
- Prior art date
Links
- 239000002184 metal Substances 0.000 title abstract 3
- 229910052751 metal Inorganic materials 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000007909 solid dosage form Substances 0.000 abstract 2
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 239000004721 Polyphenylene oxide Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 229920000570 polyether Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568914P | 2011-12-09 | 2011-12-09 | |
| US201161568890P | 2011-12-09 | 2011-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089122A1 true AR089122A1 (es) | 2014-07-30 |
Family
ID=48574916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104611A AR089122A1 (es) | 2011-12-09 | 2012-12-07 | Formulaciones orales para tratar la sobrecarga de metales |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8993606B2 (enExample) |
| EP (1) | EP2787994A4 (enExample) |
| JP (1) | JP2015500294A (enExample) |
| AR (1) | AR089122A1 (enExample) |
| AU (1) | AU2012347595A1 (enExample) |
| BR (1) | BR112014013985A2 (enExample) |
| CA (1) | CA2857990A1 (enExample) |
| TW (1) | TW201338777A (enExample) |
| WO (1) | WO2013086312A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102111176B1 (ko) | 2011-12-16 | 2020-05-15 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 4'-데스페리티오신 유사체의 용도 |
| AU2014228308A1 (en) | 2013-03-15 | 2015-08-27 | Ferrokin Biosciences, Inc. | Polymorph forms of desazadesferrithiocin analogs |
| JP6838966B2 (ja) * | 2013-11-22 | 2021-03-03 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | デスフェリチオシン類似体およびその使用 |
| JP2018515475A (ja) | 2015-04-27 | 2018-06-14 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 代謝的にプログラムされた金属キレーターおよびその使用 |
| WO2018104130A1 (en) | 2016-12-07 | 2018-06-14 | Lumileds Holding B.V. | Flash light emitter with remote communication function |
| US20220273634A1 (en) * | 2019-07-19 | 2022-09-01 | Vifor (International) Ag | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) |
| US20250268878A1 (en) | 2021-01-20 | 2025-08-28 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610644B8 (pt) | 2005-04-04 | 2021-05-25 | Univ Florida | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. |
| US8067451B2 (en) * | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
| US8324397B2 (en) | 2007-03-15 | 2012-12-04 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
| MY163516A (en) * | 2008-07-14 | 2017-09-15 | Ferrokin Biosciences Inc | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| BR112012001761A2 (pt) | 2009-07-27 | 2017-05-09 | Ferrokin Bioscience Inc | composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo |
| JP5925679B2 (ja) | 2009-08-25 | 2016-05-25 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | デスフェリチオシンポリエーテル類似体およびその使用 |
| US20130053387A1 (en) | 2010-05-04 | 2013-02-28 | FerroKin BioScience, Inc. | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
-
2012
- 2012-12-07 AU AU2012347595A patent/AU2012347595A1/en not_active Abandoned
- 2012-12-07 BR BR112014013985A patent/BR112014013985A2/pt not_active IP Right Cessation
- 2012-12-07 CA CA2857990A patent/CA2857990A1/en not_active Abandoned
- 2012-12-07 WO PCT/US2012/068432 patent/WO2013086312A1/en not_active Ceased
- 2012-12-07 US US13/708,087 patent/US8993606B2/en not_active Expired - Fee Related
- 2012-12-07 TW TW101146269A patent/TW201338777A/zh unknown
- 2012-12-07 AR ARP120104611A patent/AR089122A1/es not_active Application Discontinuation
- 2012-12-07 JP JP2014546115A patent/JP2015500294A/ja active Pending
- 2012-12-07 EP EP12856135.4A patent/EP2787994A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015500294A (ja) | 2015-01-05 |
| US8993606B2 (en) | 2015-03-31 |
| US20130225645A1 (en) | 2013-08-29 |
| TW201338777A (zh) | 2013-10-01 |
| BR112014013985A2 (pt) | 2017-06-13 |
| EP2787994A1 (en) | 2014-10-15 |
| EP2787994A4 (en) | 2015-08-26 |
| WO2013086312A1 (en) | 2013-06-13 |
| AU2012347595A1 (en) | 2014-06-26 |
| CA2857990A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CO6470847A2 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| CO2018013717A2 (es) | Piridinas sustituidas como inhibidores de dnmt1 | |
| AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| UY33606A (es) | DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112016000909A8 (pt) | derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| BR112015000106A2 (pt) | moduladores heterocíclicos de síntes de lipídio | |
| NI201100158A (es) | Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona | |
| DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO6541528A2 (es) | Derivados de la cromenona | |
| UY32582A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero | |
| CO7280475A2 (es) | Derivados de azaindol que actuan como inhibidores de pi3k | |
| MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| UY36124A (es) | Derivados de carboxamida | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| UY36123A (es) | Derivados de carboxamida | |
| UY33019A (es) | Nuevos derivados de 2-aminotiadiazol | |
| UY33745A (es) | Derivados de difenilamina: usos, procedimiento de síntesis y composiciones farmacéuticas | |
| AR120158A2 (es) | Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |